Straits Times Index
3,303.66 +12.96 (+0.39%) S&P 500
5,220.71 -1.97 (-0.04%) Dow
39,442.72 -70.12 (-0.18%) Nasdaq
16,382.95 +42.08 (+0.26%) Bitcoin USD
62,979.80 +1,668.32 (+2.72%) CMC Crypto 200
1,294.37 +34.16 (+2.71%)
IMAC Holdings, Inc. (BACK)
| Previous close | 3.4000 |
| Open | 3.4400 |
| Bid | 3.2600 x 100 |
| Ask | 3.3700 x 100 |
| Day's range | 3.2501 - 3.6368 |
| 52-week range | 1.2180 - 7.7500 |
| Volume | |
| Avg. volume | 1,022,493 |
| Market cap | 3.766M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.8200 |
| Earnings date | 13 May 2024 - 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
GlobeNewswireIMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business
FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ: BACK) (“BACK”) and Theralink Technologies, Inc. (“Theralink”), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK’s agreement to issue certain shares of preferred stock of BACK to Theralink and/or certai
GlobeNewswireCingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
Announcement Follows Recent Public Offering and Successful Capital Raising ActivityKANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of t
GlobeNewswireTheralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Golden, Colorado & Nashville, Tennessee, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein array) technology that can help predict which FDA-approved drug is effective in each cancer, today with its merger partner, IMAC Holdings, INC (Nasdaq: BACK), announce that the companies have responded to the SEC’s first round of comments on the jointly filed form S-4. A Form S-4 i
